J.C. Soria

3.8k citations

124 papers · 2.8k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in

Oncology 84
- Cancer Immunotherapy and Biomarkers 24
- Lung Cancer Research Studies 23
- Colorectal Cancer Treatments and Studies 17
- HER2/EGFR in Cancer Research 13
Pulmonary and Respiratory Medicine 63
- Lung Cancer Treatments and Mutations 50
- Lung Cancer Diagnosis and Treatment 11

Co-authors: Aurélien Marabelle Guido Kroemer Laurence Zitvogel Jonathan M. Pitt Alexander Eggermont Fabrice André Benjamin Besse Yohann Loriot
Journals: Annals of Oncology (55 papers)European Journal of Cancer (22 papers)Journal of Clinical Oncology (21 papers)Journal of Thoracic Oncology (5 papers)British Journal of Cancer (3 papers)
Partner nations: France United States Spain

In The Last Decade

J.C. Soria

120 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy 2016 · 976 citations

Peers

Countries citing papers authored by J.C. Soria

Since Specialization

Citations

This map shows the geographic impact of J.C. Soria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C. Soria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C. Soria more than expected).

Fields of papers citing papers by J.C. Soria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C. Soria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C. Soria. The network helps show where J.C. Soria may publish in the future.

Co-authors

The 25 scholars most cited alongside J.C. Soria, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.C. Soria Line = papers co-authored together J.C. Soria links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC) Annals of Oncology ·Mihaela Aldea, Claudia Parisi, C. Liu, Luigi Cerbone, Damien Vasseur, Pernelle Lavaud, Charles Naltet, 章柳云, Anas Gazzah, Angela Botticella, Antonin Lévy, C. Le Péchoux, Jérôme Le Pavec, Olaf Mercier, Étienne Rouleau, Benjamin Besse, J.C. Soria, Fabrice Barlési, Pauline Pradère, David Planchard	2021	3
2	1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT) Annals of Oncology ·P. Martin Romano, Laura Mezquita, Ludovic Lacroix, Étienne Rouleau, Andreea Varga, Capucine Baldini, Sophie Postel‐Vinay, Luc Friboulet, Arthur Géraud, Mihaela Aldea, Anas Gazzah, Yohann Loriot, J.C. Soria, Fabrice André, Antoine Hollebecque, Benjamin Besse, Christophe Massard, Antoîne Italiano	2020	5
3	1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts) Annals of Oncology ·Roberto Ferrara, Francesco Facchinetti, Giuseppina Calareso, Sanja Balić, Diego Signorelli, Claudia Proto, Arsela Prelaj, Charles Naltet, Pernelle Lavaud, Yulius Yosandri Jerhando, Giuseppe Viscardi, Giulia Galli, Alessandro De Toma, Antonia Martinetti, Fabrice Barlési, David Planchard, J.C. Soria, Marina Chiara Garassino, Benjamin Besse, Giuseppe Lo Russo	2020	7
4	Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) Annals of Oncology ·Patrick A. Ott, Y-J. Bang, A.R. Abdul Razak, Jaafar Bennouna, J.C. Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Diane Levitan, Guisheng Zhao, Kenneth Emancipator, Karen Stein, Andrew K. Joe, Mark Ayers, Jared Lunceford, Sarina A. Piha‐Paul	2017	5
5	Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience Annals of Oncology ·zen, Eduardo Castañón, Valérie Dyevre, Sandrine Aspeslagh, Aurélien Marabelle, J. Wang, Andreea Varga, Chang Duck Kim, Vincent Ribrag, Julika Bürgin, Jean‐Marie Michot, Olivier Mir, C. Massard, Antoine Hollebecque, J.C. Soria, Capucine Baldini	2017	1
6	Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO) Annals of Oncology ·Roberto Ferrara, Caroline Caramella, Matthieu Texier, Clarisse Audigier-Valette, Laurent Tessonnier, Laura Mezquita, J. Lahmar, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Virginie Westeel, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Rémi Veillon, David Planchard, Heinrich Eufinger, Serge Koscielny, J.C. Soria, Benjamin Besse	2017	19
7	Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors Annals of Oncology ·A.T. Hastie, E. Hultengren, وحید زند, Yashwant YM, Audrey Tempere, 久仁子尾﨑, Sophie Cousin, Qais Ali, Yawen Cai, Baby Vanlalhruaii, J. H. van Roon, Gregory G. Gaden, Kelly Calton, Michael P. Kreuzer, Su-Jin Ri, J.C. Soria	2017	1
8	Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA Annals of Oncology ·Sundar Ramalingam, Thanyanan Reungwetwattana, A. Syafi' AS, Arunee Dechaphunkul, K.H. Lee, Fumio Imamura, Naoyuki Nogami, Yuichiro Ohe, Ying Cheng, Byoung Chul Cho, K. K. Ragland, Johan Vansteenkiste, A M Hunter, Chao Zhou, Jhanelle E. Gray, Rachel Hodge, Yuri Rukazenkov, J.C. Soria	2017	20
9	Rociletinib-associated cataracts in EGFR-mutant NSCLC Annals of Oncology ·Zofia Piotrowska, Rumigny Jf, Andréa Varga, Manish Thakur, V. Narayanan, Stephen V. Liu, Joel W. Neal, Marshall L. Spiegel, Benjamin Solomon, Helena A. Yu, M. Pakowski, Vassiliki A. Papadimitrakopoulou, Shirish M. Gadgeel, D. Ross Camidge, J.C. Soria, Heather A. Wakelee, Jonathan W. Goldman, Kamden R. Kopani, Lindsey Rolfe, Lecia V. Sequist	2016	2
10	Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung Annals of Oncology ·Glenwood Goss, K.H. Lee, Enriqueta Felip, Manuel Cobo, خنوس محمد الهادي, Erdem Göker, 张玉娟, (unknown), Dolores Isla, Young Joo Min, Alessandro Morabito, Nicholas Dupuis, Vikram K. Chand, Flavio Solca, Nicole Krämer, Neil Gibson, E. Ehrnrooth, J.C. Soria	2016	1
11	Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis Annals of Oncology ·J.C. Soria, Soo Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Jin‐Ji Yang, M-J. Ahn, J. Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce Aix, Yuri Rukazenkov, J.H. Kim, Tony Mok	2016	13
12	ANSELMA: ANtiangiogneic SEcond line Lung cancer Meta-Analysis in non-small cell lung cancer (NSCLC) Annals of Oncology ·J. Remon Masip, Karnila Puspita Sari, Jean‐Pierre Pignon, Benjamin Lacas, J.C. Soria, Benjamin Besse	2016	1
13	Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma Annals of Oncology ·C. Boutros, Émilie Routier, Camille Hua, Matthieu Texier, Christine Mateus, C. Libenciuc, Nicola Francis, Naima Benannoune, Séverine Le Roy, Émilie Lanoy, Jérôme Le Pavec, F. Leroy Ladurie, Franck Carbonnel, Olivier Lambotte, Hassane Izzedine, A. Berdelou, Stéphane Champiat, J.C. Soria, Alexander Eggermont, Caroline Robert	2016	1
14	Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC) Annals of Oncology ·J. Lahmar, Laura Mezquita, Serge Koscielny, Fabio Facchinetti, M.V. Bluthgen, Julien Adam, Anas Gazzah, Jordi Remón, David Planchard, J.C. Soria, Caroline Caramella, Benjamin Besse	2016	12
15	Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy Lung Cancer ·Myriam Kossaï, Boris Duchemann, C. Boutros, Caroline Caramella, Antoine Hollebecque, Eric Angevin, Chang Duck Kim, Rastilav Bahleda, E. Ileana, C. Massard, Philippe Vielh, J.C. Soria, Benjamin Besse	2015	8
16	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Annals of Oncology ·J.C. Soria, Filippo de Braud, Rastilav Bahleda, Bárbara Adamo, Fabrice André, 俊太郎小山, Angelo Delmonte, R. Cereda, 周寶玲, Jason B. Litten, Andrew R. Allen, Frédéric Dubois, jyuniti Yoshikawa, H J Shin, Maurizio D’Incalci, Massimo Zucchetti, 宮下卓也, Josep Tabernero	2014	147
17	Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) Annals of Oncology ·Paul Lorigan, J.C. Soria, Joan Stephenson, Wirda Novita, R. Gervais, V. V. Sheredin, Ian McCaffery, Laurent Macé, Jesse McGreivy, Bonnie S. Glisson	2010	6
18	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials Annals of Oncology ·Rosa Conforti, Thomas Boulet, Gorana Tomasic, E. Taranchon, R. Arriagada, M. Spielmann, I. Vitali, J.C. Soria, Thomas Tursz, Suzette Delaloge, Stefan Michiels, Fabrice André	2007	69
19	Long-Term Survival of Patients Given Hormonal Therapy for Metastatic Endometrial Stromal Sarcoma Medical Oncology ·Mohammed Qassim, J.C. Soria, Marianne Kambouchner, Pittayud Aursukitwattana, Françoise Morin, Jean‐François Morère, Antoine Martin, J.L. Breau	2003	77
20	Biologie du fibrinogène. Place de la pentoxifylline. Journal des Maladies Vasculaires ·J.C. Soria, Yu.E. Allenova	1989	1

About J.C. Soria

J.C. Soria is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Statistics and Probability and Applied Microbiology and Biotechnology, having authored 124 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (50 papers), Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Research Studies (23 papers), Cancer Genomics and Diagnostics (18 papers), Colorectal Cancer Treatments and Studies (17 papers), HER2/EGFR in Cancer Research (13 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer therapeutics and mechanisms (9 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (528 citations), Pulmonary and Respiratory Medicine (980 citations), Immunology (529 citations) and Molecular Biology (1.0k citations). J.C. Soria has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Aurélien Marabelle, Guido Kroemer, Laurence Zitvogel, Jonathan M. Pitt, Alexander Eggermont, Fabrice André, Benjamin Besse, Yohann Loriot, S. Dewas and Pierre Blanchard. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact